|
|
Safety & Watchlist
Reliable picks + red flags
|
|
Safe Pick
|
|
JNJJNJ just beat earnings and raised guidance — 64 straight years of raises
|
Johnson & Johnson reported Q2 results yesterday — $25.3 billion in revenue, up 6.6%, with adjusted earnings of $2.90 per share. They raised full-year guidance to $11.68 EPS at the midpoint. And this is a company that has increased its dividend for 64 consecutive years. Since 1963. Since Kennedy was in the White House.
The quarterly payout is $1.34, giving you $5.36 a year per share. At around $254, that's a 2.11% yield. Not flashy, but JNJ is a Dividend King — that's a company with 50 or more consecutive years of increases. Only a handful of companies on Earth qualify. JNJ is now on track to hit $100 billion in annual revenue for the first time in its 140-year history.
This is the kind of name I put in the “never think about it again” part of my portfolio. With a payout ratio well under 50% on adjusted earnings, the dividend is covered with room to spare.
|
|
Yield: 2.11%
|
$10K invested = $211/yr
|
Paid: Quarterly
|
|
|
|
Red Flag
|
|
PFEPfizer yields 6.93% — and pays out more than it earns
|
I know a lot of people own Pfizer for the yield. At $24.82, with a $1.72 annual dividend, PFE yields 6.93%. That's $693 a year on $10,000. Sounds incredible next to CAT's $70 or JNJ's $211.
But here's the number that keeps me up: Pfizer's GAAP payout ratio is 130.5%. For every dollar they earn, they're sending $1.30 out the door in dividends. That's like a pizza shop where the delivery costs more than the pizza — it can work for a while, but not forever.
Management says adjusted 2026 EPS will be $2.80–$3.00, which would put the adjusted payout ratio around 60%. But “adjusted” earnings strip out a lot of real costs. And the patent cliff is real — key drugs are losing exclusivity, and replacing that revenue is like running up a down escalator. It's possible, but you have to run fast.
The ex-dividend date is July 24 — next Friday. If you own PFE, I'm not saying sell. But watch the free cash flow number closely in the next earnings report. If FCF can't cover the dividend, that 6.93% yield is living on borrowed time.
|
|
|
|
|
The Extra Yield
This week's calendars, screens & answers
|
|
Don't miss these ex-dates: CAT goes ex-dividend Monday July 20 at the new $1.63 rate. Procter & Gamble (PG) also goes ex July 24 at $1.0885. Pfizer (PFE) goes ex July 24 at $0.43. If you own any of these and want the next payment, make sure you're holding before the ex-date.
|
|
I ran a screen this morning: Cintas (CTAS) — the company that supplies uniforms and first-aid kits to businesses — reported blowout fiscal Q4 results yesterday. Revenue up 8.9% to $2.91 billion. Adjusted EPS grew 18.3%. The payout ratio is just 35%. Not a household name, but one of the steadiest dividend growers in the S&P 500.
|
|
Someone asked me: “What happens if I buy CAT on Monday the 20th instead of Friday?” You'd miss this quarter's $1.63 payment. The ex-dividend date is the cutoff — buy before it, you get paid. Buy on or after it, you wait until next quarter. For CAT, that means waiting until November.
|
|
|
|
The Dispatch
|
Today was about which direction the yield is heading. Caterpillar and MSCI are growing their payouts at 8% and 20% a year — small yields today, but they won't stay small. JNJ just proved again why 64 years means something. And Pfizer's 6.93% yield deserves a harder look at the math underneath. Tomorrow I'll tie the whole week together in the Friday roundup. Have a good Thursday night.
See you tomorrow.
|
|
— Charlie
|
|
|
|